Home  »  Trending   »  Wall Street Pummels Synthetic Biologics Inc. (SYN)...

Wall Street Pummels Synthetic Biologics Inc. (SYN) After Recent Earnings Report

Synthetic Biologics Inc. (AMEX:SYN) went up by 6.08% from its latest closing price compared to the recent 1-year high of $5.57. The company’s stock price has collected 10.56% of gains in the last five trading sessions.

Is It Worth Investing in Synthetic Biologics Inc. (AMEX :SYN) Right Now?

Plus, the 36-month beta value for SYN is at 1.37. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Synthetic Biologics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $16.25, which is $14.68 above the current price. Today, the average trading volume of SYN was 133.57K shares.

SYN’s Market Performance

SYN stocks went up by 10.56% for the week, with a monthly drop of -28.64% and a quarterly performance of -38.43%, while its annual performance rate touched -69.22%. The volatility ratio for the week stands at 11.24% while the volatility levels for the past 30 days are set at 10.47% for Synthetic Biologics Inc. The simple moving average for the period of the last 20 days is -11.11% for SYN stocks with a simple moving average of -42.57% for the last 200 days.

Analysts’ Opinion of SYN

Many brokerage firms have already submitted their reports for SYN stocks, with FBR & Co. repeating the rating for SYN by listing it as a “Outperform.” The predicted price for SYN in the upcoming period, according to FBR & Co. is $6 based on the research report published on January 06th of the previous year 2017.

FBR Capital, on the other hand, stated in their research note that they expect to see SYN reach a price target of $9, previously predicting the price at $10. The rating they have provided for SYN stocks is “Outperform” according to the report published on May 06th, 2016.

FBR Capital gave a rating of “Outperform” to SYN, setting the target price at $10 in the report published on February 26th of the previous year.

SYN Trading at -19.87% from the 50-Day Moving Average

After a stumble in the market that brought SYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.84% of loss for the given period.

Volatility was left at 10.47%, however, over the last 30 days, the volatility rate increased by 11.24%, as shares sank -31.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.60% lower at present.

During the last 5 trading sessions, SYN rose by +10.56%, which changed the moving average for the period of 200-days by -64.01% in comparison to the 20-day moving average, which settled at $1.7298. In addition, Synthetic Biologics Inc. saw -42.32% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for SYN

Equity return is now at value -22.60, with -20.50 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 19.37.